Cargando…
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice
Gallbladder cancer (GBC) is a highly malignant tumor characterized by a poor response to chemotherapy and radiotherapy. We evaluated the in vitro and in vivo antitumor efficacy of mTOR inhibitors, rapamycin and WYE-354. In vitro assays showed WYE-354 significantly reduced cell viability, migration a...
Autores principales: | Weber, Helga, Leal, Pamela, Stein, Stefan, Kunkel, Hana, García, Patricia, Bizama, Carolina, Espinoza, Jaime A., Riquelme, Ismael, Nervi, Bruno, Araya, Juan C., Grez, Manuel, Roa, Juan C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741647/ https://www.ncbi.nlm.nih.gov/pubmed/26397134 |
Ejemplares similares
-
Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
por: Weber, Helga, et al.
Publicado: (2017) -
WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines
por: Ibrahim, Sara M., et al.
Publicado: (2019) -
Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020) -
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
por: Riquelme, Ismael, et al.
Publicado: (2015) -
Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer
por: García, Patricia, et al.
Publicado: (2020)